- Home
- NXL
as 11-14-2024 3:35pm EST
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 10.0M | IPO Year: | 2022 |
| Target Price: | $3.00 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $4.36 | Next Earning Date: | 11-08-2024 |
| Revenue: | $162,078 | Revenue Growth: | 26.00% |
| Revenue Growth (this year): | 51.39% | Revenue Growth (next year): | 177.11% |
Latest Nexalin Technology Inc. News
NXL Breaking Stock News: Dive into NXL Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Nexalin Technology CEO Provides Letter to Shareholders
Simply Wall St.
5 days ago
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?
GlobeNewswire
14 days ago
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
MT Newswires
14 days ago
Nexalin Technology Regains Nasdaq Compliance Over Minimum Bid Price; Shares Rise
GlobeNewswire
14 days ago
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
ACCESSWIRE
14 days ago
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
18 days ago
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
Benzinga
18 days ago
EXCLUSIVE: Nexalin Technology Says New Data Confirms Investigational Non-Invasive Neurostimulation Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients (UPDATED)
Compare NXL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXL Nexalin Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.